ArticleInternational journal of cancer2026
A comparison by mismatch repair status of real-world characteristics and outcomes in patients with stage II/III rectal cancer in the Netherlands.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Practice Guidelines Series: Resectable Colorectal Cancer.Annals of surgical oncology · 2026Review
- A comparison by mismatch repair status of real-world characteristics and outcomes in patients with stage II/III rectal cancer in the Netherlands.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
A subset of rectal cancer (RC), <5%, exhibits mismatch repair deficiency (dMMR); the remaining are classified as proficient (pMMR). Reported evidence on differences between dMMR and pMMR RC is limited. In this nationwide Dutch study, we compared patients with dMMR and pMMR stage II/III RC based on patient and tumor characteristics, treatment patterns, and associated outcomes. Patients diagnosed between 2015 and 2022 with known mismatch repair status were selected from the Netherlands Cancer Registry. Demographic, tumor, and treatment characteristics were compared in the total cohort. Subsequently, dMMR patients were matched 1:2 to pMMR patients on age, year of diagnosis, clinical tumor stage, and node stage. Overall survival (OS) and event-free survival (EFS) were analyzed using Kaplan-Meier estimates and Cox proportional hazard models. Among 7937 eligible patients, 182 (2.3%) had dMMR RC. These patients were younger and had more poorly differentiated tumors, more variation in histology, more advanced clinical stages, and more B-RAF proto-oncogene serine/threonine kinase mutations. In the total cohort, OS was better for dMMR compared with pMMR (hazard ratio [HR] = 0.62 [95% confidence interval [CI] 0.43-0.91]). In the matched cohort, dMMR continued to exhibit improved OS (HR = 0.54 [95% CI 0.33-0.88]), and demonstrated improved EFS (HR = 0.43 [95% CI 0.29-0.63]) after adjustment for potential confounders. dMMR RC is a rare entity associated with younger age and more advanced stages. Although patients with dMMR RC had significantly improved OS and EFS compared with patients with pMMR RC, immunotherapy may further enhance outcomes. This real-world study provides a basis for future investigations aimed at optimizing therapeutic strategies for patients with dMMR RC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.